The DOI matches its Crossref record; 81 of the 88 references it cites were found in a registry or an index.
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Open accessAbstract
Glioblastoma multiforme (GBM) is a devastating disease and the most lethal of adult brain tumors. Treatment is based on surgery, radiotherapy and chemotherapy by oral temozolomide (TMZ), which is the most potent chemotherapy agent for the treatment of GBM. Despite TMZ efficiency, the prognosis of these tumors remains poor. This is because of inherent or acquired resistance of glioma tumor cells to TMZ. This resistance is caused by DNA repair enzyme activity, overexpression of epidermal growth factor receptor (EGFR), galectin-1, murine double minute 2 (Mdm2), p53 and phosphatase and tensin homolog (PTEN) mutations. Many strategies to overcome this resistance have been developed. In this review, we will describe the main mechanisms of GBM resistance to TMZ and different strategies developed to reverse the phenotype of these tumor cells. Finally, we will discuss the drawbacks and limitations of these strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
Wood, R., Mitchell, M., Sgouros, J., & Lindahl, T. (2001) · Science · doi:10.1126/science.1056154 · Cited by 1,719
Galectins as modulators of tumour progression
Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339
Cited by
Sorted by citations
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 422
New insights into long noncoding RNAs and their roles in glioma
Peng, Z., Liu, C., & Wu, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0812-2 · Cited by 375
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 335
Targeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 306
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261
Metadata
- Authors
- Messaoudi, K., Clavreul, A., & Lagarce, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Lagarce, Frédéric
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 20
- Issue
- 7
- Pages
- 899-905
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2019154144
- Cited by
- 238
- References
- 88
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 19 · 2023: 22 · 2022: 21 · 2021: 27 · 2020: 42 · 2019: 25 · 2018: 29 · 2017: 23 · 2016: 16 · 2015: 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- Ligue contre le Cancer, Comité du Maine et Loire, France
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, temozolomide, drug resistance, DNA repair, EGFR overexpression, galectin-1, MDM2, p53, PTEN mutation, resistance reversal strategies, brain tumors
- MeSH terms
- Temozolomide, Animals, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Phenotype, Structure-Activity Relationship, Biomarkers, Tumor, Drug Design, Molecular Structure, Signal Transduction, Antineoplastic Agents, Alkylating, Drug Resistance, Neoplasm, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
